Press releases

11
Apr 2018
06:00 E.S.T.

Cellectis to Present Data at the 2018 AACR Annual Meeting

Read more
10
Apr 2018
20:10 E.S.T.

Cellectis Announces Closing of Follow-On Offering

Read more
9
Apr 2018
12:30 E.S.T.

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-­oncology Portfolio

Read more
5
Apr 2018
00:30 E.S.T.

Cellectis Announces Pricing of Follow-On Offering

Read more
3
Apr 2018
20:51 E.S.T.

Cellectis Announces Launch of Follow-On Offering

Read more
3
Apr 2018
12:10 E.S.T.

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

Read more
13
Mar 2018
20:30 E.S.T.

Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor

Read more
12
Mar 2018
20:52 E.S.T.

Cellectis Reports 4th Quarter and Full Year 2017 Financial Results

Read more
8
Mar 2018
21:30 E.S.T.

Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting

Read more
13
Feb 2018
05:00 E.S.T.

Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US